Xenetic Biosciences, Inc. (NASDAQ:XBIO) Stock Short Interest Report for September

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large drop in short interest in September. As of September 30th, there was short interest totaling 12,868 shares, a drop of 42.7% from the September 15th total of 22,465 shares. Based on an average daily volume of 277,145 shares, the short-interest ratio is presently 0.0 days. Currently, 0.6% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

Xenetic Biosciences Stock Performance

Xenetic Biosciences stock opened at $2.01 on Friday. Xenetic Biosciences has a 52-week low of $1.87 and a 52-week high of $4.94. The firm has a 50 day moving average price of $3.16 and a two-hundred day moving average price of $3.04.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%. The firm had revenue of $0.66 million during the quarter.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for oncology. The company’s research is centered on treatments for difficult-to-treat cancers, including hematologic malignancies.

Xenetic’s principal technology is XCART, a personalized chimeric antigen receptor T-cell therapy platform designed to create individualized treatments that target tumor-specific antigens on a patient’s cancer cells. The platform has been developed with an initial focus on B-cell malignancies, including multiple myeloma, where tumor heterogeneity can limit the effectiveness of conventional therapies.

The company’s activities primarily involve research, preclinical development and clinical advancement of its oncology pipeline through collaborations and strategic partnerships.